Major study to track Real-World success of new kidney disease drugs

NCT ID NCT06242327

Recruiting now Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times

Summary

This observational study follows 500 adults with primary membranous nephropathy and nephrotic syndrome who are treated with rituximab or similar antibody drugs. Researchers will track how well the disease responds over time and what factors predict better outcomes. The goal is to understand real-world effectiveness of these advanced treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

ASST HPG23 - Unità di Nefrologia
ACTIVE_NOT_RECRUITING

Bergamo, BG, 24127, Italy
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
RECRUITING

Ranica, BG, 24020, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MEMBRANOUS NEPHROPATHY